Efficacy and Safety of Topiramate for Prophylactic Treatment of Children Suffering from Moderate Migraine: A Randomized Controlled Trial

Authors

  • Banita Mistry Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Most Shameem Ara Begum Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Nazmul Haq Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Most Samsun Nahar Sumi Junior Consultant, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Palash Kanti Mistry Registar, National Institute of Ophthalmology & Hospital, Dhaka, Bangladesh
  • Narayan Saha Professor & Head, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/jninb.v8i1.59927

Keywords:

Moderate migraine; topiramate; efficacy

Abstract

Background: Paediatric migraine is the most common cause of recurrent headache in children.

Objective: The purpose of the study was to assess the efficacy and tolerability of topiramate for prophylactic treatment of children suffering from moderate migraine.

Methodology: This randomized controlled trial was done in the outpatient department of Paediatric Neurology at National Institute of Neurosciences, Dhaka, Bangladesh from January to July, 2018. Children of 5 to 15years with migraine of moderate intensity were randomized into study group (TPM treatment group) and control group (FNZ treatment group). The efficacy and safety of TPM was assessed after 4 months of treatment.

Results: There was significant reduction of frequency of headache /month in both groups after treatment (within group, 4.65 ± 1.59 vs1.70 ± 0.73, p <0.001 for FNZ, 5.20 ± 1.73 vs 1.75 ± 0.71, p <0.001 for TPM). The efficacy of two drugs was not different in moderate intensity of migraine p being 0.304 and 0.828.

Conclusion: Topiramate is effective as well as safe in prophylaxis of children suffering from moderate migraine.

Journal of National Institute of Neurosciences Bangladesh, January 2022; 8(1):19-22

Downloads

Download data is not yet available.
Abstract
2
PDF
2

Downloads

Published

2022-05-27

How to Cite

Mistry, B. ., Ara Begum, M. S., Haq, N. ., Nahar Sumi, M. S., Mistry, P. K. ., & Saha, N. . (2022). Efficacy and Safety of Topiramate for Prophylactic Treatment of Children Suffering from Moderate Migraine: A Randomized Controlled Trial. Journal of National Institute of Neurosciences Bangladesh, 8(1), 19–22. https://doi.org/10.3329/jninb.v8i1.59927

Issue

Vol. 8 No. 1 (2022)

Section

Original Research Articles

License

Copyright (c) 2022 Banita Mistry, Most Shameem Ara Begum, Nazmul Haq, Most Samsun Nahar Sumi, Palash Kanti Mistry, Narayan Saha

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright on any research article in the Journal of National Institute of Neurosciences Bangladesh is retained by the author(s).

The authors grant the National Institute of Neurosciences Bangladesh a license to publish the article and identify itself as the original publisher.

Articles in the Journal of National Institute of Neurosciences Bangladesh are Open Access articles published under the Creative Commons CC BY-NC License (https://creativecommons.org/licenses/by-nc/4.0/)

This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and it is not used for commercial purposes.